Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 8/20 | 0.47 |
| ▸ | TTK | P33981 | 5/20 | 0.44 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123990 | 1.00 | PTK6 (0.47) | PTK6TTKLCKCDK1CDK2 | |
| SCHEMBL22125448 | 0.90 | TTK (0.51) | TTKCDK1CDK2MCHR1ATR | |
| SCHEMBL22124013 | 0.89 | PTK6 (0.52) | PTK6TTKLCKAURKBMAPKAPK5 | |
| SCHEMBL22124280 | 0.89 | PTK6 (0.46) | PTK6TTKLCKAURKB | |
| SCHEMBL22123985 | 0.88 | PTK6 (0.46) | PTK6TTKLCKAURKB | |
| SCHEMBL22124015 | 0.86 | PTK6 (0.44) | PTK6TTKLCKAURKB | |
| SCHEMBL22123966 | 0.86 | PTK6 (0.49) | PTK6TTKLCKAURKBMAPKAPK5 | |
| SCHEMBL22124498 | 0.85 | PTK6 (0.53) | PTK6TTKLCKAURKBMAPKAPK5 | |
| SCHEMBL30171606 | 0.85 | PTK6 (0.53) | PTK6TTKLCKAURKBMAPKAPK5 | |
| Hydrochloric Acid SCHEMBL30171611 | 0.85 | PTK6 (0.48) | PTK6TTKLCKAURKBMAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885TTK 4546/4885LCK 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.